. Author manuscript; available in PMC: 2020 Apr 1.

Published in final edited form as: Am J Transplant. 2018 Dec 6;19(4):1150–1159. doi: 10.1111/ajt.15148

Table 4:

Adjusted hazard of cardiovascular events by induction agent, stratified by gender, race, donor source, age, diabetes mellitus, steroid maintenance and acute rejection

	ATG		AZM		No induction
	aHR (95% CI)	p value for interaction	aHR (95% CI)	p value for interaction	aHR(95% CI)	P value for interaction
Gender
Male	0.92 (0.85–1.00)	0.01	0.99 (0.84–1.16)	0.5	1.03 (0.96–1.12)	0.2
Female	1.08 (0.98–1.19)	0.01	1.06 (0.88–1.29)	0.5	1.12 (1.02–1.24)	0.2
Race
Non-AA	0.99 (0.91–1.07)	0.7	0.99 (0.85–1.17)	0.6	1.04 (0.97–1.12)	0.3
AA	0.97 (0.87–1.08)	0.7	1.06 (0.87–1.29)	0.6	1.12 (1.00–1.24)	0.3
Donor type
LD	0.94 (0.80–1.10)	0.5	0.85 (0.63–1.14)	0.2	1.00 (0.88–1.14)	0.3
DD	0.99 (0.92–1.06)	0.5	1.05 (0.91–1.21)	0.2	1.08 (1.01–1.16)	0.3
Age
Age<65	0.97 (0.90–1.05)	0.8	1.03 (0.89–1.19)	0.7	1.06 (0.99–1.14)	0.8
Age ≥ 65	0.99 (0.88–1.12)	0.8	0.98 (0.77–1.23)	0.7	1.08 (0.96–1.21)	0.8
Diabetes
Yes	1.04 (0.96–1.13)	0.01	1.04 (0.87–1.23)	0.8	1.07 (0.99–1.15)	0.8
No	0.89 (0.81–0.98)	0.01	1.00 (0.84–1.20)	0.8	1.08 (0.98–1.19)	0.8
Steroid maintenance
Yes	1.00 (0.93–1.07)	0.1	1.07 (0.87–1.32)	0.3	1.07 (1.00–1.14)	0.7
No	0.86 (0.72–1.03)	0.1	0.92 (0.75–1.13)	0.3	1.03 (0.84–1.26)	0.7
One-year acute Rejection
Yes	1.04 (0.88–1.22)	0.6	1.46 (1.12–1.92)	0.005	0.97 (0.83–1.14)	0.2
No	0.99 (0.92–1.06)	0.6	0.97 (0.84–1.12)	0.005	1.08 (1.01–1.16)	0.2

AA: African American, AZM: alemtuzumab, ATG: anti-thymocyte globulin, CI: confidence interval, CVE: cardiovascular events, DD: deceased donor, IL-2RA: IL-2 receptor antagonist, LD: living donor